Traditional Chinese Medicine in Treating Hypertension

Li J · Circulation: Cardiovascular Quality and Outcomes · 2022 March

Objective

To demonstrate that a Chinese herbal patent formula, Songling Xue-maikang Capsules (SXC), was non-inferior to losartan in reducing office diastolic BP after an 8-week treatment.

Conclusions

These promising findings indicate that SXC has the potential to replace losartan or other ACE inhibitors/angiotensin receptor blockers in treating mild essential hypertension, rather than merely acting as complementary medicine.

Critical Appraisal

Published research can offer valuable insights, but a paper’s conclusions may go beyond what its results support. Critical appraisal examines the methods, findings and limitations to clarify what can reasonably be concluded—and what remains uncertain.

This article has not yet been critically appraised by the Research Hub.

Learn more about Critical Appraisal